Cancer Survival DOUBLED? New mRNA Vaccine Data from China (LK101 & EVM14)

24 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Data from top oncologists suggests that combining mRNA vaccines with immunotherapy could effectively DOUBLE survival rates for advanced cancer patients. But how does it work, and where can you access it?

In this video, we break down the latest insights from Dr. Qiu Lixin (Fudan University Shanghai Cancer Center) and Dr. Tang Rijie regarding the revolutionary "LK101" and "EVM14" mRNA cancer vaccines emerging in China.

Read the full breakdown and see the survival charts here: https://www.medbridgenz.com/post/mrna-cancer-vaccine-china-immunotherapy

In this video, we cover:
* The MD Anderson data: Why immunotherapy alone might not be enough.
* How adding an mRNA vaccine increased median survival from 20.6 to 37 months.
* The difference between "Personalized" (LK101) and "Off-the-shelf" (EVM14) vaccines.
* The current landscape of Medical Tourism China for accessing these clinical trials.

About MedBridgeNZ: Navigating the Chinese medical system for advanced treatments like mRNA clinical trials can be complex. MedBridgeNZ is a premier medical concierge provider. We are NOT a hospital and do not provide medical services directly. Instead, we act as your bridge—handling logistics, hospital connections, translations, and travel arrangements—so you can focus on your recovery.

Learn more about our services: https://www.medbridgenz.com/

⚠️ Medical Disclaimer: The content in this video is for informational purposes only and is based on translated materials from Dr. Qiu Lixin and Dr. Tang Rijie. MedBridgeNZ is a medical concierge service facilitator, not a medical professional. This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your oncologist or other qualified health provider with any questions you may have regarding a medical condition.

Sources: Insights adapted from:
* Dr. Qiu Lixin (Fudan University Shanghai Cancer Center)
* Dr. Tang Rijie (Guangdong Pharmaceutical University Guangzhou Fosun Chancheng Hospital)

#mRNACancerVaccine #MedicalTourismChina #Immunotherapy #CancerResearch #LungCancer #Melanoma #ChinaMedical #MedBridgeNZ #LK101
Categoria
Oncology
Commenta per primo questo video.

Prossimo